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One of the diﬃculties in developing countermeasures to biothreat agents is the challenge inherent in demonstrating their eﬃcacy
in man. Since the ﬁrst publication of the Animal Rule by the FDA, there has been increased discussion of potential correlates of
protection in animal models and their use to establish surrogate markers of eﬃcacy in man. The latter need to be relatively easy
to measure in assays that are at least qualiﬁed, if not validated, in order to derive a quantitative assessment of the clinical beneﬁt
conferred. The demonstration of safety and clinical beneﬁt is essential to achieve regulatory approval for countermeasures for
which clinical eﬃcacy cannot be tested directly, as is the case for example, for biodefence vaccines. Plague is an ancient, serious
infectious disease which is still endemic in regions of the modern world and is a potential biothreat agent. This paper discusses
potential immune correlates of protection for plague, from which it may be possible to derive surrogate markers of eﬃcacy, in
order to predict the clinical eﬃcacy of candidate prophylaxes and therapies.
1.Plague
The ancient disease of plague is still present in endemic
regions of the modern world and results in approximately
3,000 reported cases each year [1]. Plague is a ﬂea-vectored
infection caused by the Gram-negative bacterium Yersinia
pestis, a potential biothreat agent. Originally an enteric
pathogen, Y. pestis is thought to have evolved from the
enteropathogen Y. pseudotuberculosis [2]a saﬂ e a - v e c t o r e d ,
enzootic infection. Fleas feed on infected rodents and then
transmit bacteria to a susceptible mammal by ﬂea bite. Man
is an accidental host in this cycle, but if bitten can contract
bubonic plague, a serious infection if not treated promptly
before the individual becomes symptomatic. A secondary
pneumonic plague can develop in an individual suﬀering
from bubonic plague, and this is of even greater concern,
since Y. pestis bacteria are highly transmissible in aerosolised
form between unprotected individuals in close contact, with
the potential for epidemic spread [3].
2.VirulenceFactorsinYersinia pestis
Y. pestis produces a range of antigens and virulence factors,
three of which have known protective eﬃcacy as candidate
subunit vaccines: F1-antigen [4], V-antigen [5], and Yersinia
secretory factor F (YscF) [6]. These three proteins are viru-
lence factors when secreted by Y. pestis during infection. F1
antigen is a capsular protein with antiphagocytic properties
[7], whilst the V-antigen is a regulatory protein in the
type three secretion system (TTS) utilised by the bacterium
to gain access to and deliver other cytotoxic and anti-
phagocytic Yersinia outer proteins (Yops) to host cells [8]. V-
antigen occurs both within the bacterium, where it has some
regulatory function in the initiation of the TTS process, and
also at the tip of the injectisome [9]. The columnar structure
of the injectisome is comprised of YscF [6].
Many other factors have been evaluated as potential
vaccine candidates, including for example plasminogen
activator (Pla), which during infection facilitates the delivery
of the blood meal from the infected ﬂea into mammalian
host cells, by the degradation of physical barriers such as
endothelium and connective tissue [10, 11]. However, Pla
was found to be poorly immunogenic and provided no
protection against lethal plague in a mouse model [11].
YscF has also been evaluated for eﬃcacy [6], as has ph6
antigen [12] and many of the Yop’s [13, 14]. Whilst some
of these factors confer partial protection in animal models
of plague, full protective eﬃcacy against Y. pestis has been2 Advances in Preventive Medicine
achievedonlywithF1-orV-antigensandwasoptimumwhen
these antigens were used in combination, or as a genetic
fusion [15, 16] .T h ep r o t e c t i v ee ﬃcacy of the combined
recombinant F1 and V (rF1+rV) subunits against Y. pestis
has now been reported by a number of laboratories and
in a range of laboratory animal models (reviewed in [17]).
Immunisation with rF1/V has been shown to protect animal
models against ﬂea-vectored plague [18]a sw e l la sa g a i n s t
experimental exposure to Y. pestis [19, 20].
3.Vaccinationto ProtectagainstPlague
Vaccination and postexposure therapy are both options to
protect individuals against exposure to Y. pestis. There has
been a series of killed whole cell vaccines (KWCVs) for
plague, starting with Haﬀkine’s vaccine in the late 1800s
[21], through to the currently available KWCV produced by
the Central Serum Laboratories (CSL), which comprises a
suspensionofheat-killedY. pestis (>109/mL).WhilstKWCVs
are eﬃcacious against bubonic plague, epidemiological
evidence suggests that they have little protective eﬃcacy
against pneumonic plague [15, 20, 22, 23]. F1 appears
to be the key protective antigen in KWCV formulations,
which thus do not protect against F1− Y. pestis [4, 5].
Unlike the KWCVs, the rF1-/V-antigen combination has
been demonstrated to protect both mice and macaques
againstpneumonicplague[24–27],representingasigniﬁcant
advance in candidate countermeasures for plague infection.
Diﬀerent presentations of F1/V have been studied including
D N Av a c c i n e s[ 28], oral formulations [29], and live vaccine-
vectored expression from, for example, salmonella strains
[30].
A naturally attenuated live vaccine strain, EV76, has been
demonstrated to protect mice and macaque models against
pneumonic plague [31, 32] .R e c e n t l y ,as t r a i no fY. pestis
KIM, mutated to stimulate TLR4 responses in the vaccinee,
has been mooted as a vaccine candidate, protecting 80%
of vaccinated mice against pneumonic plague [33]. This
diﬀerential between live attenuated and killed vaccines in
eﬃcacy against pneumonic plague has been attributed to
lack of the V-antigen in the KWCV formulations which
contain eﬀective quantities of the F1-antigen only [15, 26];
bycomparison,liveattenuatedvaccinescontainbothF1-and
V-antigens [15]. However, live attenuated vaccines such as
EV76, have caused morbidity in nonhuman primates (NHP)
[34], raising safety concerns over their use in man.
4. Postexposure Therapy
The early detection and administration of antibiotic therapy
within 18–24 hours following suspected exposure to Y. pestis
and before the appearance of symptoms, is critical for the
successful treatment of plague. The recommended antibiotic
regimen comprises a high dose of gentamicin intravenously
(5mg/kg intravenously once a day) or the equivalent dosage
of streptomycin, ciproﬂoxacin, gentamicin, or doxycycline
for 10 days [35]. Chloramphenicol may also be used if plague
meningitis is suspected [36]. As the patient responds to
treatment, it may be possible to change to the oral route
of administration of the preferred antibiotic. It is essential
that antibiotic treatment is adjusted dependent on the
antibiotic susceptibility of the infecting organism in culture,
particularly if deliberate use of an antibiotic- resistant strain
is suspected.
In animal models, the administration of monoclonal
antibodies (Mab’s) with speciﬁcity for F1 and V, has been
shown to protect mice infected with Y. pestis, even when
the Mab’s were administered at 48h post-exposure [37].
However, the protective eﬀect of the anti-V Mab 7.3 was
abrogated by the coadministration of anti-TNFα and anti-
IFNγ indicating that a cellular proinﬂammatory response
is also contributing to protection [38]. There is scope for
combining immuno- and antibiotic therapy after exposure
to Y. pestis, in order to shorten the duration of antibiotic
therapy required.
5. Bridging betweenNonclinicalandClinical
Since standard Phase III clinical eﬃcacy studies are not
feasible to carry out with plague and other serious human
diseases, on both ethical and practical grounds (too few
naturally occurring cases as well as outbreaks which are
spasmodic), it is essential to establish satisfactory animal
modelsofthedisease.These,inturn,canbeusedtoassessthe
eﬃcacy of candidate vaccines and therapies and to identify
correlates of protection. Robust animal models of plague
infection which authentically represent the human disease
syndromearetheobjectiveandmodelshavebeenestablished
in standard laboratory animal species (mouse, rat, rabbit,
and macaque), as well as nonstandard species such as the
black-footed ferret (reviewed in [17]).
The rF1/V combination is potently immunogenic in
the mouse, guinea pig, macaque, and human [15, 39–
41] and has been shown to be eﬃcacious in nonclinical
models against either injected [15], aerosolised [16, 20], ﬂea-
vectored [18], or ingested [42]e x p o s u r et oY. pestis.F r o m
these nonclinical studies, there is a need to identify the
immune correlates of protection to facilitate the progression
of candidate countermeasures through the clinical phase.
Bridging the gap between the nonclinical and clinical
phases of the development process for a countermeasure is
arguably the most risky element of the entire R&D cycle
and has previously been termed “the valley of death” [43].
Many candidate prophylaxes and therapies have foundered
at this interface, possibly because of the diﬃculty in
comparing nonclinical and clinical datasets in terms of
protectiveeﬃcacy.Thishighlightstheneedtounderstandthe
immunological mechanisms required to achieve protective
eﬃcacy against such agents and to derive immune correlates
of protection in animal models. Identiﬁcation of the latter,
based on immunological readouts which have been found to
correlate statistically with protective eﬃcacy in appropriate
animal models, should lead to the derivation of surrogate
markers of eﬃcacy (Figure 1). Surrogate markers need to
be measurable and quantitative endpoints for clinical trial
volunteerswhichpredicteﬃcacy.Ifseveralsurrogatemarkers
are used, collectively these may be used to predict the degree
of eﬃcacy that can be achieved. Thus the nomination ofAdvances in Preventive Medicine 3
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Figure 1: Integrating immunological readouts from nonclinical
and clinical studies to identify surrogate markers of eﬃcacy.
surrogate markers of eﬃcacy eﬀectively bridges the gap
between the nonclinical and clinical phases of R&D.
Depending on how closely the animal model mimics
the human infection, more than one animal model of the
infection may be required to provide immune correlates,
concepts embodied in the Animal Rule by the Food and
Drug Agency in the USA [44]. In summary, the Animal Rule
requires the following:
(1) there is a well-understood pathophysiological mech-
anism operating and of its prevention or substantial
reduction by the product;
(2) the eﬀect is demonstrated in one or more animal
species expected to react with a response predictive
for humans, unless the eﬀect is demonstrated in a
single animal species that represents a suﬃciently
well-characterized animal model for predicting the
response in humans;
(3) the animal study endpoint is clearly related to the
desired beneﬁt in humans, generally the enhance-
ment of survival or prevention of major morbidity;
(4) the data or information on the kinetics and pharma-
codynamics of the product in animals and humans,
allows selection of an eﬀective dose in humans.
Having identiﬁed immune correlates of protection, there
are various mathematical approaches to extrapolate these
nonclinical data to man in order to predict degrees of
protection [45].
6. Immune Correlates of Protection in Plague
Immunisation of mice with either [4, 5]o rb o t hF 1a n d
V proteins [15, 16] was protective against plague and a
titre of speciﬁc antibody correlated with protection. Whilst
the development of an IgG titre to these proteins correlates
with protection as observed in mice [46], guinea pig [39],
nonhuman primate (NHP) [40] and inferred from passive
transfer studies with clinical trial serum [41], neutralizing
antibody alone does not describe the entire mechanism of
protection against this virulent pathogen [17]. Researchers
from several groups have reported a strong CMI response to
be operating [38, 47, 48] and in response to an alhydrogel-
adsorbed formulation of the rF1+rV vaccine, this generally
has been observed to be a CD4+Th2-biased CMI response
[46]. However, alternative formulations of the rF1+rV
vaccine in which diﬀerent adjuvants have been substituted
for alhydrogel have also been demonstrated to induce
protective immunity in a CD4+Th1-biased setting [49, 50].
Additionally, strains of mice with targeted gene deletions
aﬀecting antibody production by B cells (μMT B cell knock-
outs or SCID/beige) or the nature of the Th cell response
including Stat 4/Stat 6 knockouts and IL4/IL10 knockouts
have been studied [17, 49–51]; rF1+rV-immunised Stat-4-
deﬁcient mice, which have low levels of IFNγ production,
were found to be poorly protected from Y. pestis challenge,
despite producing similar antibody titres to rF1+rV as
the intact controls [49]. Moreover, the rF1+rV vaccine
was able to induce protective immunity in IL4 knockout
mice despite a Th1-biased environment operating in these
animals [50]. Indeed, Stat-4-mediated immune mechanisms
leading to a Th1 response were found to be essential for
protection, whereas Stat 6/Th2-mediated responses were not
[49]. Thus for the rF1+rV vaccine, the induction of speciﬁc
antibody neutralising the F1 and V antigens is a signiﬁcant
immune correlate of protection; however the supporting
CMI response is not necessarily Th2-polarised and indeed
the operation of Th1 mechanisms during infection appears
to be essential for full protection and recovery [17].
Whilst the measurement of total Ig indicates that an
immune response has been induced by a candidate vac-
cine, this alone cannot indicate that protective immunity
has been achieved. The assay of the functionality of the
induced antibody may be more instructive. If protection
can be demonstrated in the selected animal models and
related to the presence of a neutralising antibody response,
then the identiﬁcation of the same neutralising antibody
within serum samples from human clinical trial volunteers
indicates an immune correlate of protection and potential
surrogate marker of eﬃcacy. Thus immune macaque [40]
and human Phase 1 trial volunteers [41]s e r ah a v eb e e n
demonstrated to compete with the plague-protective mon-
oclonal antibody (Mab 7.3) for binding to the V-antigen
on solid phase in vitro; these sera (results not shown) as
well as Mab 7.3 protected J774 cells in vitro from the
cytotoxic eﬀect of V-antigen secreted by Y. Pseudotuberculosis
(Figure 2); passively protected naive mice from in vivo
challenge with Y. pestis. The passive transfer of protective
immunity in human serum into mice also correlated sig-
niﬁcantly with the total IgG titre in the human donors
to rF1+rV at days 21 (P<0.001) and 28 (P<0.03)
[41].
Subsequently however, competitive ELISA has not been
shown to be consistent between laboratories as a correlate of
protectionassay[52],likelyduetotheexistenceofmorethan
one protective B-cell epitope on the V antigen [53]. Thus
a pragmatic approach towards assays showing a correlation
between immunological readouts in relevant animal models
and man needs to be taken to thoroughly test such assays for
consistency and utility.4 Advances in Preventive Medicine
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Figure 2: The cytoxicity of Y. pestis V antigen expressed from Y. pseudotuberculosis for J774 cells was inhibited by pretreatment with anti-V
Mab 7.3. Cells were stained with ethidium bromide/acridine orange to identify live cells (green) and dead cells (red). (a) Unifected J774
cells, (b) J774 cells infected with Y. pseudotuberculosis expressing V antigen were killed, shown by the preponderance of dead cells. (c) J774
cells pretreated with Mab 7.3 prior to exposure to Y. pseudotuberculosis expressing V antigen were protected, with no signiﬁcant diﬀerence in
appearance, compared with uninfected cells.
7. PotentialSurrogateMarkers of Efﬁcacy for
Countermeasuresto Plague
Based on these data on immune correlates and on the
immunoanalysis data published to date on samples from
clinical trial volunteers immunised with the rF1/V subunit
vaccine [41], it is possible to identify several serological sur-
rogate markers of eﬃcacy. These may include the inhibitory-
activity of human immune serum on the cytotoxicity of V-
antigen secreted from Y. pseudotuberculosis. Qualitative data
from this assay have been published [40], however, the assay
hassubsequentlybeenimprovedandmadequantitative[54].
It has been demonstrated that decreased caspase-3 activity
in macrophages exposed to immune NHP serum correlated
with increased survival of those NHP to Y. pestis infection.
Passive transfer of human serum from volunteers
enrolled in a Phase I clinical trial has been demonstrated to
protect naive mice against plague infection, in a dose-related
manner [41]. The passive transfer of protective immunity
into mice also correlated signiﬁcantly with total IgG titer to
r F 1p l u sr Va td a y s2 1( r2 = 98.6%; P<0.001) and 28
(r2 = 76.8%; P<0.03).
Assays for cellular surrogate markers of eﬃcacy have
traditionally been more challenging, particularly in a clinical
setting, since they have required fresh whole blood samples
and relatively prompt analysis. However recent advances in
ﬂow cytometry have simpliﬁed this, allowing the assay of T-
cell responses and the quantitative analysis of lymphocyte
subsets in whole blood. Nevertheless, sample size is impor-
tant: attempts to analyse changes in cell surface markers
on peripheral blood mononuclear cells (PBMC) by ﬂow
cytometry during the course of a small Phase 1 clinical trial
for rF1V did not reveal any signiﬁcant trends, due to the
large variation in response between individuals [41]. The
demonstration of a cellular recall response to rF1/V has
been reported in ex vivo splenocytes from immunised mice
[55]. A more practical alternative may be to use an ELIspot
assay, where for example, IFNγ secretion from splenocytes
restimulated in vitro with vaccine antigens is detected [48].
More speciﬁcally, CD4+ T-cell epitopes for F1 and V have
been identiﬁed in mice [56, 57] and an H-2d-restricted
murine T-cell epitope in F1 has been shown to be essential
f o rp r o t e c t i o ni nB a l b / cm i c e[ 58]. Similarly, HLA-restricted
T-cell epitopes have been mapped in F1 [59] and are being
sought in V-antigen using HLA transgenic mice. These data
mayinthefutureprovidefunctionaltargetsforhumanT-cell
memory responses, recognition of which by immune PBMC
could provide a cellular surrogate marker of eﬃcacy.Advances in Preventive Medicine 5
8. Conclusions
Much work is ongoing to identify statistically valid immune
correlates of protection for plague, particularly since a
clinical demonstration of eﬃcacy is not possible. This has
required the development of nonclinical models which
authentically represent the human infection. As far as pos-
sible, the immune correlate should be demonstrated in more
than one nonclinical model. Whilst the immune correlate(s)
may not describe all the immune mechanisms operating in
protection against a pathogen, they should be reproducibly
consistent between the selected nonclinical models and
the clinic and should be quantitative, to assess the likely
beneﬁt to be conferred on the vaccinee. With an increasing
understanding of the molecular basis of pathogenicity and
of the innate and adaptive immune response mechanisms
required to counter Y. pestis, immune correlates of protection
are being identiﬁed and reported and this in turn will
expedite the development of next-generation vaccines and
immunotherapies.
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